Leviticus Cardio announces success of six-month chronic animal study

Editor’s note: News of the Leviticus announcement appeared on PRNewswire and Yahoo! Finance.

Leviticus Cardio, inventors of the versatile transcutaneous Coplanar Energy Transfer (CET) system used with implanted left ventricular assist devices (LVADs), announces the successful completion of a 180-day preclinical chronic animal study to evaluate its CET technology in combination with a commercial heart pump.

Leviticus’ CET technology compliments a LVAD made by Jarvik Heart Inc. which is equipped with a post auricular pedestal, acting together as a hybrid system for the subject.

The ongoing trial is being conducted at a renowned animal facility operated by the Catholic University of Leuven, Belgium.

This comes as Leviticus has raised additional funds to proceed with the first in human (FIH) trial.

Michael Zilbershlag, Leviticus Cardio’s CEO, says, “The combination of the success of the trial reaching six months and the additional resources we have received, means we have what we need to move on to the first in human stage.”

“This milestone is a watershed moment for the CET system. The ongoing longevity of the subject gives hope that soon human beings might be able to reap its benefits.” stated Professor Ivan Netuka, MD, Ph.D. of the Institute for Clinical and Experimental Medicine (IKEM), Prague.

Peter Hinchliffe, Jarvik Heart Inc. president and COO, stated: “The synergy between Jarvik Heart and Leviticus technologies continues to show clear benefits. Our companies look forward to providing a complete wireless VAD system which will change patients’ lives.”